Comparative efficacy and safety of novel Lp(a)-lowering therapies for ASCVD prevention: A network meta-analysis

Elevated lipoprotein(a) [Lp(a)] is a genetically determined and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) that is largely resistant to conventional lipid-lowering therapies. Novel Lp(a)-targeted agents, including small interfering RNA (siRNA), antisense oligonucleoti...

ver descrição completa

Detalhes bibliográficos

Principais autores:	An-xin Wu, Xing-jin Wang, Chen Zhao, Jia-qiang Hu, Jin-wei Li, Ying Xu, Yi Li, Song Liu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-05-01
coleção:	Pharmacological Research
Assuntos:	Small interfering RNA Antisense oligonucleotides Muvalaplin Lp(a) LDL-C Network Meta-Analysis
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1043661826000939
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!